|
|
|
| Therapeutic effect of epalrestat combined with beraprost sodium on diabetic peripheral neuropathy |
|
TANG Shan1, MEI Hong2, WEN Hong-hua1, LI Dan2, ZHU Qun1 |
| （1. Department of Endocrinology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu 210011; 2. Department of Endocrinology,the Yuejiang Tower Community Health Centre,Gulou District,Nanjing Jiangsu 210011,China)
|
|
|
|
|
Abstract Objective: To investigate the therapeutic effect of epalrestat combined with beraprost sodium on diabetic peripheral neuropathy(DPN). Methods: A total of 96 patients with DPN were randomly divided into epalrestat group(n=32), beraprost sodium group(n=32) and epalrestat combined with beraprost sodium group(n=32).After 12 weeks treatment, the clinical effect and motor conduction velocity and sensory conduction velocity of median nerve, peroneal nerve were measured in three groups. Results: There were statistically significant differences in therapeutic efficacy among three groups(P<0.05), epalrestat combined with beraprost sodium in treatment of DPN exerted the best efficacy. The nerve conduction velocity of the three groups was improved compared with before that treatment(P<0.05). With regard to nerve conduction velocity improvement in three groups, epalrestat combined with beraprost sodium group had more rapid velocity than the other two groups(P<0.05). Conclusion: Epalrestat combined with beraprost sodium in treatment of DPN could produce best therapeutic efficacy.
|
|
Received: 19 March 2017
|
|
|
|
| [1\]PopBusui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association\[J\]. Diabetes Care, 2017, 40(1): 136-154.\[2\]臧丽, 巴建明. 糖尿病周围神经病变的诊治\[J\]. 中华临床医师杂志(电子版), 2013, 7(8): 3257-3259.\[3\]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation\[J\]. Diabet Med, 1998, 15(7): 539-553.\[4\]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)\[J\].中华内分泌代谢杂志, 2014, 30(8): 2-42.\[5\]刘世明, 张娟, 成百朵. 甲钴胺、贝前列腺素钠口服治疗糖尿病周围神经病变疗效观察\[J\]. 现代中西医结合杂志, 2015, 24(32): 3575-3577.\[6\]Cakici N, Fakkel TM, Van Neck JW, et al. Systematic review of treatments for diabetic peripheral neuropathy\[J\]. Diabet Med, 2016, 33(11): 1466-1476.\[7\]Lechleitner M, Abrahamian H, Francesconi C, et al. Diabetic neuropathy\[J\]. Wien Klin Wochenschr, 2016, 128(Suppl 2):S73-79.\[8\]Zhou J, Zhou S. Inflammation: therapeutic targets for diabetic neuropathy\[J\]. Mol Neurobio, 2014, 49(1): 536-546.\[9\]Sasaki H. Pathophysiology, neurological examinations and diagnosis of diabetic polyneuropathy\[J\]. Nihon Rinsho, 2012, 70(Suppl 5):445-450.\[10\]黄耀宁, 韦洪江. α硫辛酸联合甲钴胺治疗糖尿病周围神经病变的疗效及对氧化应激的影响 \[J\]. 山东医药, 2013, 53(8): 13-15.\[11\]Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy\[J\]. Pharmacotherapy, 2008, 28(5): 646-655.\[12\]Ohmura C, Watada H, Azuma K, et al. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes\[J\]. Endocr J, 2009, 56(1): 149-156.\[13\]Yoon HS, Choi WJ, Sung IH, et al. Effects of Beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease\[J\]. Clin Orthop Surg, 2013, 5(2): 145-151.\[14\]Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments\[J\]. Lancet Neurol, 2012, 11(6): 521-534. |
|
|
|
2017, Vol. 27 
